A Dose-Ranging Study of Fluticasone Propionate in Adult Patients With Moderate Asthma

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects

“…The cortisol suppression seen in the present study is more pronounced compared with that in some studies in asthmatic In an overview of the clinical and pharmacological properties, FP was said to have an elimination half-life of patients [2, 17,18]. This may be explained by differences in the methods used; due to the diurnal variation of plasma around 10 h (range 7-14), and a maximum accumulation ratio of 1.4 after repeated inhalation for 7 days [16].…”

“…plasma cortisol concentrations have been reported in most clinical trials with FP without any information about To conclude, a slow elimination of FP leads to accumulation during repeated dosing. This accumulation may variability [2, [17][18][19]. The difference in the sensitivity of various methods does not exclude the possibility that explain the marked decrease in plasma cortisol suppression seen during treatment with fluticasone propionate within differences between healthy subjects and asthmatic patients in lung deposition or sensitivity of the HPA-axis to the clinical dose range.…”

Difficult asthma

“…One of the gray areas is whether further increases in dose will bring further benefit. Studies of dose-response relationships of inhaled GCS indicate there is a progressively diminishing response above 800 lg/day of budesonide or 400 lg/day fluticasone propionate (75,76). Individuals may, however, respond to higher doses.…”

Is Fluticasone Propionate Superior to the Other Available Inhaled Steroids?

“…Third, studies in both adults and children have consistently demonstrated FP to be more effective than beclomethasone dipropionate and budesonide on a microgram-per-microgram basis. As discussed in Dr. Storms' review, studies comparing FP to beclomethasone dipropionate have shown FP to be approximately twice as potent in terms of improving peak expiratory flow rate (PEFR) (12,13). It should be noted that equal improvement in efficacy parameters while patients are receiving different doses of inhaled GC (e.g., x pg/day of GC A vs. 2x pg/day of GC B) does not necessarily demonstrate that GC A is twice as potent as GC B (14).…”